232 related articles for article (PubMed ID: 22493730)
1. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
[TBL] [Abstract][Full Text] [Related]
2. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich A
IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
[TBL] [Abstract][Full Text] [Related]
4. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
5. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
Wada Y; Lu R; Zhou D; Chu J; Przewloka T; Zhang S; Li L; Wu Y; Qin J; Balasubramanyam V; Barsoum J; Ono M
Blood; 2007 Feb; 109(3):1156-64. PubMed ID: 17053051
[TBL] [Abstract][Full Text] [Related]
6. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Toichi E; Torres G; McCormick TS; Chang T; Mascelli MA; Kauffman CL; Aria N; Gottlieb AB; Everitt DE; Frederick B; Pendley CE; Cooper KD
J Immunol; 2006 Oct; 177(7):4917-26. PubMed ID: 16982934
[TBL] [Abstract][Full Text] [Related]
7. Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate.
Oehrl S; Olaru F; Kunze A; Maas M; Pezer S; Schmitz M; Schäkel K
J Dermatol Sci; 2017 Sep; 87(3):278-284. PubMed ID: 28732748
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model.
Chen HH; Chao YH; Chen DY; Yang DH; Chung TW; Li YR; Lin CC
Int Immunopharmacol; 2016 Apr; 33():70-82. PubMed ID: 26874324
[TBL] [Abstract][Full Text] [Related]
10. Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin.
Orlik C; Deibel D; Küblbeck J; Balta E; Ganskih S; Habicht J; Niesler B; Schröder-Braunstein J; Schäkel K; Wabnitz G; Samstag Y
Cell Mol Immunol; 2020 Apr; 17(4):380-394. PubMed ID: 31324882
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.
Yawalkar N; Tscharner GG; Hunger RE; Hassan AS
J Dermatol Sci; 2009 May; 54(2):99-105. PubMed ID: 19264456
[TBL] [Abstract][Full Text] [Related]
12. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
14. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
15. Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.
Li Y; Golden JB; Camhi MI; Zhang X; Fritz Y; Diaconu D; Ivanco TL; Simon DI; Kikly K; McCormick TS; Wang Y; Ward NL
J Invest Dermatol; 2018 Feb; 138(2):310-315. PubMed ID: 28951241
[TBL] [Abstract][Full Text] [Related]
16. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
Kim J; Krueger JG
Annu Rev Med; 2017 Jan; 68():255-269. PubMed ID: 27686018
[TBL] [Abstract][Full Text] [Related]
17. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
[TBL] [Abstract][Full Text] [Related]
18. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.
Haider AS; Lowes MA; Suárez-Fariñas M; Zaba LC; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG
J Immunol; 2008 Feb; 180(3):1913-20. PubMed ID: 18209089
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R; Barish CF; Riff D; Pruitt R; Chey WY; Farraye FA; Shafran I; Katz S; Krone CL; Vander Vliet M; Stevens C; Sherman ML; Jacobson E; Bleday R
Inflamm Bowel Dis; 2006 Jul; 12(7):558-65. PubMed ID: 16804392
[TBL] [Abstract][Full Text] [Related]
20. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
